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Meconium in the amniotic fluid was found in 2,633 obstetri-
cal patients and meconium-aspiration occurred in 77 cases out 
of 14,527 deliveries. Although the incidence of meconium in 
the amniotic fluid increased significantly at 39 weeks, a corre-
sponding significant increase in meconium-aspiration did not 
occur until 41 weeks gestation. All deaths associated with 
meconium, as well as 84% of the cases of severe meconium-
aspiration syndrome, occurred in infants born of patients with 
oligohydramnios and a gestational age of 41 weeks or greater. 
Introduction 
The incidence of meconium-stained amniotic fluid appears 
to increase with gestational age1·2 but the significance of 
meconium has been controversial as a risk-factor for adverse 
perinatal outcome. Meconium does increase the potential for 
perinatal morbidity and mortality when it is associated with 
the meconium-aspiration syndrome. The majority of cases of 
meconium-aspiration syndrome has occurred in association 
with fetal distress3·5 but meconium-aspiration has been noted 
in the presence of a normal fetal heart-rate pattem6 and prior 
to the onset of active labor7 • The purpose of our study was to 
document the incidence of meconium present in the amniotic 
fluid, and to see if a correlation existed with the meconium-
aspiration syndrome and advancing gestational age. 
Materials and Methods 
A detailed review of 14,527 deliveries during the past 2 
consecutive years identified 2,633 cases of meconium in the 
amniotic fluid and 77 cases of meconium-aspiration syn-
drome. All pregnancy and fetal outcomes were obtained from 
a careful review of the prenatal, labor and delivery, and 
neonatal records. Gestational age was determined from a 
review of menstrual history, ultrasound examination and 
antenatal records. The gestational ages of all 77 mothers 
whose infants had meconium-aspiration syndrome were doc-
umented by early ultrasound. 
Meconium was graded by the physician in attendance as 
thick, moderate, or thin. The presence of meconium in amni-
otic fluid obtained preterm was confirmed by spectrophoto-
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metric analysis. In the infant, the diagnosis of meconium-
aspiration required finding meconium in the trachea, clinical 
signs of respiratory distress, and a chest x-ray consistent with 
meconium-aspiration. Oligohydramnios was diagnosed by 
ultrasound or by the clinical absence of fluid in the mother 
documented during labor and delivery. 
Meconium-aspiration was considered to be severe when 
infants had to be placed on a respirator for ventilatory sup-
port. All infants with the syndrome were subjected to aggres-
sive airway management. This included pharyngeal function-
ing with a DeLee catheter at delivery of the head, followed by 
visualization of the vocal cords and suctioning of the trachea 
under direct vision by a member of the pediatric house staff. 
Obstetrical patients who had meconium in the amniotic fluid 
and whose infants developed the meconium-aspiration syn-
drome were analyzed in relation to gestational age. Statistical 
evaluation was done by chi square analysis; the probability 
was considered to be significant at P=<0.05. 
Results 
The presence of meconium was documented in 2,633 
cases (18%) out of 14,527 deliveries between 28 and 45 
weeks of gestation. The syndrome itself was diagnosed in 77 
deliveries (0.05% ). Between 28 and 36 weeks' gestation, 
meconium was found in 153 cases (1 0. 7%) out of 1,426 
deliveries. Between 37 and 41 weeks, meconium was found 
in 2,305 cases (18.5%) out of 12,487 deliveries. After 41 
weeks, meconium was found in 175 cases (28.5%) out of 614 
deliveries. The incidence of parturient patients who had 
meconium in the amniotic fluid, and whose infants went on to 
have the meconium-aspiration syndrome, remained relatively 
constant with increasing gestational age from 28 to 36 weeks 
(Table 1). However, at 39 weeks the incidence increased con-
siderably, followed by a significant increase in the meconi-
um-aspiration syndrome in the infant at 41 weeks (Table 2). 
A significant increase in the meconium-aspiration syndrome 
occurred in cases that demonstrated meconium in the amniot-
ic fluid pre-delivery at 41 weeks (Table 3). 
The aspiration of meconium by the infant was diagnosed in 7 
patients who delivered prior to 38 weeks' gestation. Four of these 
demonstrated thin meconium and 3 had moderately thick meconi-
um. Very thick meconium was not found in any infant with the 
aspiration syndrome whose mother delivered prior to the 38-week 
period. On the other hand, at 39 weeks and beyond, 91% of the 
infants with the syndrome presented with very thick meconium. 
Oligohydramnios was characteristic of 29 out of 31 moth-
ers (94%) whose infants demonstrated the meconium-aspira-
tion syndrome, mothers whose· gestational ages were 41 
weeks or beyond. 
There was a 63% rate of fetal distress and a 57% rate of 
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delivery by C-section in the cohort of women whose infants 
were diagnosed as having the syndrome. However, of the 
women who had oligohydramnios at 41 weeks or beyond, 90% 
exhibited fetal distress and 83% of them had to have C-sections. 
Term infants with the syndrome spent a mean of 4 days in 
the neonatal intensive care unit and were hospitalized for an 
average of 11 days in all. Severe aspiration of meconium was 
diagnosed in 84% of the infants delivered at 41 weeks' gesta-
tion and beyond. The 3 infants who died of meconium-aspira-
tion were delivered by cesarean section, the indication being 
TABLE 1: Gestational Age, Meconium Staining of Amniotic Fluid 
and Mtconlum-Aipll'lflon Syndrome 
Gestational Deliveries Meconium Pertenlllge Meconium Percentage 
Age Staln ng Deliv8 Asp ration Oeltvaries 
28 60 11 18.3% 1 17% 
29 37 3 8.1% 0 -
30 74 10 13.5% 0 -
31 69 8 116% 0 -
32 119 IS 12.6% 1 0.8% 
33 138 12 8.7% 0 -
34 191 20 10.5% 3 1.6% 
36 47~ 44 9.3% 1 0.2% 
TABLE 2: Geltltlonal Age, Meconium Staining of Amniotic Auld 
and Mtconlum·Aipii'IHon Syndrome 
Geslll1lonal Dehver1es Mecon urn P rtentlge Meconium Percentage 
Age Staining Deliveries Asp'ra1lon Deliveries 
37 963 115 119% 1 01% 
38 2.1n 281 12.9% 7 0.3% 
39 3.~93 621 17.7% 9 03% 
40 4,165 874 21.0% 22 05% 
41 1.689 414 24.5% 21 2%' 
42 518 151 292% 10 1.90% 
43 ~ 20 23.8% 0 -
'' Po<O 005 bttWIIIIIht cumnlllld pttvlous wteiiS ot P/'IGNilCY 
TABLE 3: Gntatlonal Age and Meconium-Aspiration Syndrome In 
Patients with Meconium at Birth 
Gesta onal Meconium Meconium Perten ge 
Percentage II 8 rth Asp rauon 
I 
37 60 11 18.3% 
38 37 3 81% 
39 74 10 135% 
~0 69 8 11.6% 
41 119 15 126% 
42 138 12 8.7% 
43 191 20 10.5% 
' 'Po<O 025 belwltn 1111 CUIIIIllllld pfi'AouJ wab of PI1Qr.IIICI' 
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fetal distress; all 3 were found to have aspirated thick meconi-
um. Two of these infants were delivered after 41 weeks of 
gestation, and the third was delivered after 42 weeks. 
Comment 
In this study meconium was found to be present in 10.7% 
of the infants delivered preterm. Matthews and Warshaw2 did 
not find any meconium in patients at less than 34 weeks of 
gestation, but Parida8 found meconium in 3.7% of such cases. 
Ostrea and Naqvi9 found a 2.6% incidence in their preterm 
patients. Green and PauP0 found a 6% incidence between 29 
and 36 weeks of gestation, and in 8% of their patients prior to 
29 weeks' gestation. 
In our study, spectrophotometric analysis used to document 
the presence of meconium in the amniotic fluid could account 
for the higher percentage of preterm patients positive for the 
presence of meconium. Although meconium was found in 
10.7% of preterm patients, the incidence of meconium-aspira-
tion in the infants delivered remained at a low of 0.5%. A sig-
nificant increase in the presence of meconium was document-
ed at 39 weeks' gestation. This increase at 39 weeks also has 
been reported by Eden' and Green'0 and represents a normal 
physiologic indicator of fetal maturation" or compression of 
the cord in the mature fetus12 • 
The impression that the presence of meconium alone, in 
the absence of any other risk factors, is a normal result of fetal 
maturation can be supported by the uneventful outcome of the 
majority of fetuses delivered despite the presence of meconi-
um as reported in all studies10• 
The significant increase in meconium at 39 weeks docu-
mented in our study was not accompanied by an increase in 
the meconium-aspiration syndrome until 41 weeks of gesta-
tion had been reached. This appears to confirm the finding 
that meconium alone is not a good predicter of adverse fetal 
outcome'3 ; other factors besides the presence of meconium 
must be taken into account. 
When fetal asphyxia is associated with meconium, it appears 
that the potential for perinatal morbidity and mortality is 
increased14·15 • Miller has suggested that fetal asphyxia with the 
presence of meconium can increase the potential for meconium-
aspiration and poor neonatal outcome'6• Grausz and Heirnler 
reported that 5% of infants who died of unexpected asphyxia 
did so prior to 40 weeks' gestation, compared to 32.5% at 40 to 
41 weeks and 37.5% after 41 weeks 17 • A similar gestational age 
distribution was found in their neurologically affected group of 
infants which led to the conclusion that pregnancies beyond 40 
weeks require meticulous assessment of fetal well-being both 
before and during labor because this is the most frequently 
observed time for unexpected asphyxia'7 • 
A decrease in amniotic fluid appears to be another factor in 
the meconium-aspiration syndrome. Amniotic fluid volume 
remains relatively constant until the 37th week of gestation; it 
declines gradually until the 40th week. After 40 weeks, amni-
otic fluid diminishes rapidly in a certain percentage of 
patients; the lowest amniotic fluid volumes are found at 41 
weeks' gestation or later '8• Of greater importance, is 
Clement's report that amniotic fluid volume could decrease 
significantly in less than 24 hours in post-dated pregnancies'9• 
Based on these studies, it appears that the fetus beyond 40 
weeks with meconium in the amniotic fluid and oligohydram-
nios in the mother is at very high risk for developing unex-
pected fetal asphyxia. The decrease in volume can lead to the 
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meconium being thicker, which would make it more difficult 
for the trachea to be cleared at the time of delivery. 
Decreasing amniotic fluid volume also can also lead to com-
pression of the umbilical cord causing a further expression of 
meconium into the amniotic fluid. This would increase the 
likelihood of the in utero infant aspirating the meconium20• 
In our study, the incidence of aspiration of meconium 
remained at a relatively low level between 28 and 40 weeks 
of gestation. The incidence increased after 40 weeks' gesta-
tion and rose significantly at 41 weeks. All fetal deaths and 
84% of the severe cases of meconium-aspiration in this study 
occurred at 41 weeks and beyond. In some centers, there is a 
trend to begin the induction of labor or surveillance of the 
fetus at the end of 41, and even 40, completed weeks 
because of a small number of unexplained stillbirths21 • It 
appears that delivery prior to 41 weeks in a patient with 
oligohydramnios and the presence of meconium would sig-
nificantly decrease the incidence of the most serious compli-
cations associated with the meconium-aspiration syndrome. 
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